Six-month weight loss up to the time of diagnosis and symptom distress were evaluated to determine their effects on quality of life for patients with esophageal cancer treated with surgery and chemotherapy.
Researchers sought to determine whether screening patients with MM after ASCT with FDG-PET would be able to identify patients with residual disease.
Osimertinib and chemotherapy is more effective than osimertinib alone as first-line treatment for patients with EGFR-mutant, advanced NSCLC, phase 3 data suggest.
More than twofold increase in risk seen for those treated with ≥200 mg/m² cumulative doxorubicin versus no doxorubicin.
Researchers evaluated data from 270 patients with MM undergoing spine surgery to determine complication and reoperation rates.
The US supply of cisplatin is nearly restored, and shortages of carboplatin and methotrexate have been alleviated, the government says.
Patritumab deruxtecan (HER3-DXd) is effective in patients with previously treated, EGFR-mutant NSCLC, a phase 2 study suggests.
Urine albumin-creatinine ratio significantly higher for patients receiving dasatinib.
Financial hardship related to treatment costs is a common reality for many men with metastatic prostate cancer.
Chemotherapy alone may produce better outcomes than surgery plus chemotherapy in patients with mesothelioma, the MARS 2 trial suggests.
